Select a medication above to begin.
Simlandi (adalimumab-ryvk)
adalimumab
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in pts w/ chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections incl. Legionella and Listeria observed; some infections have been fatal; most infections occur in combo w/ other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during adalimumab tx; initiate anti-TB tx before adalimumab tx; monitor for infection s/sx during and after adalimumab tx; since active TB has developed in pts w/ negative tuberculin skin test, monitor all pts for active TB s/sx; since histoplasmosis may be present in pts w/ negative antigen and antibody tests, consider empiric antifungal tx in pts w/ severe systemic illness if at risk for invasive fungal infection; D/C adalimumab tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated w/ TNF blockers; post-marketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) reported mostly in Crohn dz or ulcerative colitis pts, mostly adolescent and young adult males receiving concomitant azathioprine or mercaptopurine; uncertain whether HSTCL related to TNF-blocker monotherapy or in combo w/ other immunosuppressants
Adult Dosing .
Dosage forms: INJ (auto-injector): 40 mg
Special Note
- [formulation clarification]
- Info: nonproprietary name = adalimumab-ryvk
rheumatoid arthritis, moderate-severe
- [40 mg SC q2wk]
- Info: may incr. dose to 40 mg SC qwk or 80 mg SC q2wk if not on methotrexate
psoriatic arthritis
- [40 mg SC q2wk]
ankylosing spondylitis
- [40 mg SC q2wk]
Crohn dz, moderate-severe
- [40 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29
ulcerative colitis, moderate-severe
- [40 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29; Info: D/C if no evidence of remission after 8wk
psoriasis, moderate-severe chronic plaque
- [40 mg SC q2wk]
- Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8
hidradenitis suppurativa, moderate-severe
- [40 mg SC qwk or 80 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
uveitis
- [40 mg SC q2wk]
- Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8; Info: for non-infectious intermediate, posterior, and panuveitis
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (auto-injector): 40 mg
Special Note
- [formulation clarification]
- Info: nonproprietary name = adalimumab-ryvk
polyarticular juvenile idiopathic arthritis, moderate-severe
- [2 yo and older, 10-14 kg (off-label)]
- Dose: 10 mg SC q2wk; Info: 10 mg injectable form not avail. for this brand, see other adalimumab products
- [2 yo and older, 15-29 kg (off-label)]
- Dose: 20 mg SC q2wk; Info: 20 mg injectable form not avail. for this brand, see other adalimumab products
- [2 yo and older, >30 kg]
- Dose: 40 mg SC q2wk
Crohn dz, moderate-severe
- [6 yo and older, 17-39 kg (off-label)]
- Dose: 20 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC x1 on day 15, then 20 mg SC q2wk on day 29; Info: 20 mg injectable form not avail. for this brand, see other adalimumab products
- [6 yo and older, >40 kg]
- Dose: 40 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29
ulcerative colitis, moderate-severe (off-label)
- [5 yo and older, 20-39 kg]
- Dose: 20 mg SC qwk or 40 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC x1 on days 8 and 15, then 20 mg SC qwk or 40 mg SC q2wk on day 29; Info: 20 mg injectable form not avail. for this brand, see other adalimumab products
- [5 yo and older, >40 kg]
- Dose: 40 mg SC qwk or 80 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on days 8 and 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 8, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
hidradenitis suppurativa, moderate-severe (off-label)
- [12 yo and older, 30-59 kg]
- Dose: 40 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8
- [12 yo and older, >60 kg]
- Dose: 40 mg SC qwk or 80 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
uveitis (off-label)
- [2 yo and older, 10-14 kg]
- Dose: 10 mg SC q2wk Info: for non-infectious intermediate, posterior, and panuveitis; Info: 10 mg injectable form not avail. for this brand, see other adalimumab products
- [2 yo and older, 15-29 kg]
- Dose: 20 mg SC q2wk; Info: for non-infectious intermediate, posterior, and panuveitis; Info: 20 mg injectable form not avail. for this brand, see other adalimumab products
- [2 yo and older, >30 kg]
- Dose: 40 mg SC q2wk; Info: for non-infectious intermediate, posterior, and panuveitis
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection risk
- caution: pts >65 yo
- caution: diabetes mellitus, uncontrolled
- caution: opportunistic infection hx
- caution: TB infection, latent
- caution: TB infection risk
- caution: residents of area w/ endemic TB
- caution: residents of area w/ endemic mycosis
- caution: travelers in area w/ endemic TB
- caution: travelers in area w/ endemic mycosis
- caution: HBV infection
- caution: HBV infection hx
- caution: malignancy hx
- caution: malignancy risk
- caution: CHF
- caution: demyelinating dz
- caution: myelosuppression
- caution: myelosuppression hx
Drug Interactions .
Overview
adalimumab
TNF blocker
- cardiotoxic effects
- immunosuppressive effects
- caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- anakinra
- anifrolumab
- baricitinib
- belimumab
- bimekizumab
- brodalumab
- canakinumab
- certolizumab pegol
- cladribine oral
- deuruxolitinib
- epirubicin
- etanercept
- etrasimod
- golimumab
- guselkumab
- idarubicin
- infliximab
- ixekizumab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- rilonacept
- risankizumab
- ritlecitinib
- rituximab
- ruxolitinib topical
- sarilumab
- secukinumab
- tildrakizumab
- tocilizumab
- tofacitinib
- upadacitinib
- ustekinumab
- vedolizumab
Monitor/Modify Tx
- ado-trastuzumab emtansine
- aldesleukin
- alogliptin
- anagrelide
- anthrax vaccine
- asciminib
- avelumab
- axitinib
- bevacizumab
- bezlotoxumab
- binimetinib
- bortezomib
- bosutinib
- capecitabine
- carfilzomib
- chikungunya vaccine
- cilostazol
- clozapine
- cobimetinib
- COVID-19 vaccine
- cyclophosphamide
- dabrafenib
- daunorubicin
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- doxorubicin
- dronedarone
- ebola vaccine, live
- encorafenib
- entrectinib
- everolimus
- fam-trastuzumab deruxtecan
- fluorouracil
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- ibrutinib
- ifosfamide
- imatinib
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- itraconazole
- Japanese encephalitis vaccine
- lapatinib
- lenvatinib
- linagliptin
- margetuximab
- mavacamten
- meningococcal vaccine
- mirdametinib
- mitoxantrone
- mobocertinib
- osimertinib
- pazopanib
- peginterferon beta 1a
- pertuzumab
- pioglitazone
- pneumococcal vaccine
- poliovirus vaccine
- ponatinib
- propafenone
- respiratory syncytial virus vaccine
- ripretinib
- ropeginterferon alfa-2b
- rosiglitazone
- saxagliptin
- selumetinib
- sipuleucel-T
- sitagliptin
- smallpox/mpox vaccine, live
- sorafenib
- sunitinib
- temsirolimus
- tick-borne encephalitis vaccine
- tivozanib
- trabectedin
- trametinib
- trastuzumab
- typhoid vaccine
- vandetanib
- zanidatamab
- zenocutuzumab
Caution Advised
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- alemtuzumab
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belinostat
- bendamustine
- betamethasone
- blinatumomab
- brentuximab vedotin
- brexucabtagene autoleucel
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- carboplatin
- carmustine
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- decitabine
- deflazacort
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- eribulin
- etoposide
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- idecabtagene vicleucel
- idelalisib
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- nelarabine
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- omacetaxine mepesuccinate
- oxaliplatin
- ozanimod
- paclitaxel
- panobinostat
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- romidepsin
- rozanolixizumab
- ruxolitinib
- satralizumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tisagenlecleucel
- topotecan
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- vamorolone
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, serious
- opportunistic infection
- tuberculosis
- HBV reactivation
- malignancy
- lymphoma
- leukemia
- skin CA
- hypersensitivity rxn
- anaphylaxis
- Stevens-Johnson syndrome
- erythema multiforme
- CHF
- neurologic disorders
- optic neuritis
- myelosuppression
- lupus-like syndrome
- vasculitis
- sarcoidosis
- interstitial lung dz
- hepatotoxicity
Common Reactions
- injection site rxn
- URI
- headache
- rash
- nausea
- UTI
- hyperlipidemia
- flu syndrome
- abdominal pain
- back pain
- HTN
- hematuria
- hypersensitivity rxn
- alk phos incr.
- ALT elevated
- CK elevated, transient (peds pts)
- arthralgia (plaque psoriasis use)
Safety/Monitoring .
Monitoring Parameters
hepatitis B serology incl. HBsAg at baseline; TB test at baseline, then periodically; active TB s/sx; dermatologic exams, especially if incr. skin CA risk
Pregnancy/Lactation .
Pregnancy
Clinical Summary
benefits outweigh risks in 1st and 2nd trimester, weigh risk/benefit in 3rd trimester; no known risk of teratogenicity based on human data; possible risk of neonatal immunosuppression based on drug's mechanism of action; for infants exposed to adalimumab in utero, avoid live vaccines for at least 6mo after birth
Lactation
Clinical Summary
may use while breastfeeding; no known risk of infant harm based on limited human data and drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: unknown; CYP450: unknown
Excretion: unknown; Half-life: 2wk
Subclass: DMARDs, Tumor Necrosis Factor (TNF) Inhibitors ; Inflammatory Bowel Disease (IBD) ; Psoriasis, Systemic Agents ; Spondyloarthropathies
Mechanism of Action
binds and inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.